Učitavanje...
Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?
BACKGROUND: The 2019 novel coronavirus disease (COVID-19) causes for unresolved reasons acute respiratory distress syndrome in vulnerable individuals. There is a need to identify key pathogenic molecules in COVID-19-associated inflammation attainable to target with existing therapeutic compounds. Th...
Spremljeno u:
| Izdano u: | Mol Med |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7203545/ https://ncbi.nlm.nih.gov/pubmed/32380958 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10020-020-00172-4 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|